<DOC>
	<DOCNO>NCT00293124</DOCNO>
	<brief_summary>The rationale assess clinical biological activity Imatinib compare data historic data . Additionally study design gain experience treatment GIST several Central Eastern European Countries .</brief_summary>
	<brief_title>Open-label Trial GlivecWith Unresectable Metastatic Malignant Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>This multicenter open label clinical trial perform patient incurable malignant GISTs unresectable metastatic . Approximately 150 patient enter trial . Patients receive Imatinib 400 mg p.o./day period 24 month provide opinion investigator patient benefiting treatment Imatinib , absence safety concern . Treatment completion 24 month study discretion investigator . Imatinib increase 600 mg p.o./day 400 mg b.i.d patient progress respective dose level .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients &gt; = 18 year age Histologically document diagnosis GIST malignant well unresectable ( =not amenable surgery curative intent ) and/or metastatic therefore incurable Immunohistochemical documentation ckit ( CD117 ) expression tumor At least one measurable site disease ( defined Southwestern Oncology Group Solid Tumor Response Criteria ) previously embolised irradiated Performance status 0,1 , 2 3 ( ECOG ) Adequate end organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL ( &lt; 5 x ULN hepatic metastasis present ) , creatinine &lt; 1.5 x ULN , ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Life expectancy least 6 month Written , voluntary , informed consent Patients previously treat chemotherapy eligible study Patient least 5 year free melanoma eligible study Patient receive investigational agent within 28 day first day study drug dose Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention CECOGs ' approval obtain , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Female patient pregnant breastfeeding . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) Patient know brain metastasis Patient acute know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) Patient know diagnosis human immunodeficiency virus ( HIV ) infection Patient receive chemotherapy within 4 week ( 6 week nitrosoureas mitomycinC ) prior study entry Patient previously receive radiotherapy &gt; = 25 % bone marrow Patient major surgery within 2 week prior study entry Patient significant history noncompliance medical regimen inability grant reliable informed consent Therapeutic anticoagulation warfarin ( e.g . Coumadin® Coumadine® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Gastrointestinal Stromal Tumors</keyword>
	<keyword>Glivec</keyword>
</DOC>